Difference between revisions of "Asparaginase (Elspar)"
m |
|||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Acute lymphocytic leukemia]] | *[[Acute lymphocytic leukemia]] | ||
| − | *[[T-cell lymphoma]] | + | *[[Extranodal NK/T-cell lymphoma, nasal type]] |
==Patient drug information== | ==Patient drug information== | ||
Revision as of 23:57, 26 November 2014
General information
Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.[1][2]
Route: IV, IM
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Asparaginase (Elspar) patient drug information (Chemocare)[3]
- Asparaginase (Elspar) patient drug information (UpToDate)[4]
Also known as
Asparaginasa, Asparaginase Medac, Chephacardin, Colaspase, Crasnitin, Elspar, Erwina Asparaginas, Erwinase, Erwinaze, Erwinia, Erwiniase, Kidrolase, L-ASP, L-Asparaginasa Filaxis, Laspar, L Asparaginasa, L Asparaginase, L Asparaginasum, Leucoginase, Leunase, Paronal